SEC Comment Letter 0000000000-23-012747 to Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Date: Nov. 21, 2023 · CIK: 0001651407 · Accession: 0000000000-23-012747
AI Filing Summary & Sentiment
File numbers found in text: 333-275644
Letter
United States securities and exchange commission logo November 21, 2023 James Oliviero Chief Executive Officer Checkpoint Therapeutics, Inc. 95 Sawyer Road, Suite 110 Waltham, MA 02453 Re:Checkpoint Therapeutics, Inc. Registration Statement on Form S-3 Filed November 17, 2023 File No. 333-275644 Dear James Oliviero: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew W. Mamak, Esq.
Show Raw Text
United States securities and exchange commission logo
November 21, 2023
James Oliviero
Chief Executive Officer
Checkpoint Therapeutics, Inc.
95 Sawyer Road, Suite 110
Waltham, MA 02453
Re:Checkpoint Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 17, 2023
File No. 333-275644
Dear James Oliviero:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew W. Mamak, Esq.